CJC/Ipa + Tesamorelin
Three compounds. Two of them open the same door.
CJC-1295 and tesamorelin are both GHRH analogs, hitting the same receptor by the same route. Tesamorelin is the only compound here with FDA approval, and the trial behind it measured about two centimetres off the waist in a population almost nobody in this stack belongs to.
The standard pair, with belly fat added to the list.
CJC-1295 with ipamorelin is the most established pairing in this category, run for deeper sleep, faster recovery from training and a slow shift in body composition. It works on a real argument: two different switches, one raising the signal that drives growth hormone release and one triggering the pulse itself.
Tesamorelin gets added because of one thing. It is the only compound in this whole category with an FDA approval attached, and that approval is specifically about reducing deep abdominal fat. Deep abdominal fat, the kind packed around the organs, is the fat that general weight loss reaches last, and it is the one people most want gone.
So the pitch is growth hormone support plus a targeted attack on the stubborn part. It is a coherent idea and it has two problems, one about the receptor and one about what the trials showed.
Fifteen percent of visceral fat. Two centimetres of waist.
Tesamorelin was approved in November 2010 on the back of two Phase 3 trials, randomised, meaning people were assigned to each group by chance, and neither patients nor doctors knew who was getting the drug and who was getting a placebo. Pooled across 806 participants, visceral fat fell by about 15.4% against placebo over 26 weeks.[1]
A 15% cut to visceral fat is a real and measurable result, and it came to about a kilogram over six months with roughly two centimetres off the waist.[2] One payer review of the evidence describes the effects as modest.[2]
The visceral selectivity is genuine and has a clear mechanism behind it. Visceral fat carries more growth hormone receptors than the fat under your skin does, so raising growth hormone moves that compartment preferentially.[3] Subcutaneous fat and limb fat barely changed in the trials.[4]
Liver fat also fell, and that finding has driven a wave of off-label use in fatty liver disease.[3]
Stop taking it and the fat comes back.
Tesamorelin does not change anything structural. It keeps growth hormone pulses elevated, and the fat responds to that while it continues.
Visceral fat returns toward where it started within roughly 24 weeks of stopping.[5] The same payer review notes the effects are not maintained beyond the duration of treatment.[2]
That turns a course into a commitment. Anyone running this for belly fat is signing up for continuous use to hold a one-kilogram result, and nobody has published long-term cardiovascular safety data to sit alongside that decision.[2]
The approval covers one group only: adults with HIV-associated lipodystrophy. That is a condition where body fat moves around into an unusual pattern. Outside that group, no comparable trial data exists.[5]
Two GHRH analogs and one secretagogue.
Growth hormone compounds reach the pituitary through one of two switches. The standard argument for stacking them is to take one from each.
Both are synthetic copies of GHRH acting on the same receptor. They differ in how long they last, since tesamorelin is stabilised against breakdown while CJC-1295 without DAC clears fast. Same door, different timing.
The other switch, covered by one compound. Ipamorelin is the selective one in its class, meaning it triggers the pulse without dragging up hunger or stress hormones the way older ones did.
So this is three purchases and two mechanisms, with a duplicate on one side. The version that follows its own logic drops one of the two GHRH analogs, and which one you drop depends on whether you want the approval behind tesamorelin or the lower price of CJC-1295.
The timing difference is a real argument and an untested one. Nobody has studied whether a long-acting GHRH copy alongside a short-acting one produces anything either would not alone.
The same shape of problem shows up in the performance recovery stack, where MK-677 and GHRP-2 duplicate each other on the ghrelin side instead.
IGF-1 from three directions, and blood sugar.
All three compounds work by raising your own growth hormone, and growth hormone drives the liver to produce IGF-1, the hormone that carries out most of its effects. IGF-1 is also the marker people track to check whether any of this is working.
In a Phase 2 trial of tesamorelin, IGF-1 rose about 53% against roughly 5% in the comparison group.[6] That is one compound on its own. This stack raises the same hormone from three directions at once, and the long-term risks of elevated IGF-1 are not established.[2]
Blood sugar is the other one. Fasting glucose rose in the tesamorelin trials, and so did HbA1c, a blood test showing average blood sugar over the previous few months. The label advises caution, and says to consider stopping if blood sugar problems or diabetes develop.[5][7] Raising growth hormone reduces insulin sensitivity generally, which is why the same warning attaches to MK-677.
Anyone running this stack has a specific reason to have IGF-1 and fasting glucose checked, and that is a conversation for a doctor rather than a forum.
What people ask about this stack
Does tesamorelin reduce belly fat?
Yes, and by less than the percentage suggests. Pooled across two Phase 3 trials of 806 participants, visceral fat fell about 15.4% against placebo over 26 weeks. In absolute terms that was roughly one kilogram and about two centimetres off the waist. Subcutaneous fat, the layer under the skin, barely changed. One payer review of the evidence calls the effects modest.
Does the effect last after stopping?
No. Visceral fat returns toward baseline within roughly 24 weeks of stopping, because tesamorelin keeps growth hormone pulses elevated rather than changing anything structural. Payer reviews note the effects are not maintained beyond the duration of treatment. Holding the result means continuous use, and there is no published long-term cardiovascular safety data for that.
Why is adding tesamorelin to CJC-1295 a problem?
They are both GHRH analogs, meaning synthetic copies of the same hormone acting on the same pituitary receptor. The difference is duration, since tesamorelin is stabilised to last longer. So this stack covers two mechanisms with three compounds, and the third is a more expensive way into a door already open. Nobody has tested whether pairing a long-acting and a short-acting GHRH copy does anything either would not alone.
What is tesamorelin approved for?
Reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition where body fat moves into an unusual pattern. That is the whole indication, granted in November 2010. Outside that population no equivalent controlled trial data exists, and every wellness or anti-ageing use is off-label.
What should be monitored?
IGF-1 and fasting glucose. All three compounds raise growth hormone, which raises IGF-1, and the long-term risks of elevated IGF-1 are not established. Fasting glucose and HbA1c rose significantly in the tesamorelin trials, and the label advises considering stopping if glucose intolerance or diabetes develops. That is a conversation for a doctor.
Is there a cheaper version of this stack?
Dropping one of the two GHRH compounds gets you the same two mechanisms. Keeping tesamorelin buys the approval and the visceral fat data; keeping CJC-1295 costs about four dollars less per vial. A premixed tesamorelin and ipamorelin blend also exists, which covers both switches in one vial. Compare against the other stacks.
What this page is built on
Tesamorelin has a real approval and real pivotal trials, so most figures here trace to named studies. The trial numbers were read through secondary summaries.
- 01Falutz et al., pivotal Phase 3 trials of tesamorelin in HIV-associated lipodystrophy. Pooled analysis of 806 participants, visceral adipose tissue reduced approximately 15.4% against placebo at 26 weeks, p less than 0.001, with concurrent falls in fasting triglycerides. A post hoc analysis of the same Phase 3 data is at PMC9947601.
- 02Payer coverage assessment of Egrifta SV. Source for the roughly 2 cm waist circumference change, the description of the effects as modest and not sustained after discontinuation, the absence of long-term cardiovascular safety data, and the note that long-term risks of elevated IGF-1 are unknown.
- 03Mechanism and trial summary: GHRH receptor binding, higher growth hormone receptor density in visceral than subcutaneous fat, 15 to 18% visceral reductions over 26 weeks, and liver fat effects driving off-label use. A related conference abstract on visceral and liver fat is at PMC10678288, DOI 10.1093/ofid/ofad500.1334.
- 04Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. DOI 10.1056/NEJMoa072375. Estimated 1.0 kg selective loss of visceral fat after six months; subcutaneous fat increased 0.4% against 1.7% on placebo; limb fat 0.6% against 3.8%.
- 05Tesamorelin results timeline and evidence assessment. Source for visceral fat returning toward baseline within approximately 24 weeks of stopping, the narrow HIV-lipohypertrophy indication, the absence of equivalent controlled data outside that population, and documented rises in fasting glucose and HbA1c.
- 06Phase II trial of tesamorelin for cognition in ageing HIV-infected persons. NCT02572323. IGF-1 rose 53.2% (95% CI 32.8 to 76.8) in the immediate group against 5.3% (95% CI minus 2.7 to 13.9) in the deferred group at week 24.
- 07FDA approval announcement for Egrifta, November 2010, including the label caution to exercise care in patients who develop glucose intolerance or diabetes and to give careful consideration to discontinuing.
- 08Peptide Decoding vendor pricing data, 12 September 2026. Lowest in-stock single-compound listings: CJC-1295 no DAC $23.99, ipamorelin $17.56, tesamorelin $20.00.